1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
    Journal Article

    Boilève, A.; Carlo, M. I.; Barthélémy, P.; Oudard, S.; Borchiellini, D.; Voss, M. H.; George, S.; Chevreau, C.; Landman-Parker, J.; Tabone, M. D.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer
    Journal Article

    Gagliano-Jucá, T.; Pencina, K. M.; Ganz, T.; Travison, T. G.; Kantoff, P. W.; Nguyen, P. L.; Taplin, M. E.; Kibel, A. S.; Li, Z.; Huang, G.; more...
    American Journal of Physiology - Endocrinology and Metabolism (2018)

    Fulltext@MSK | Save
  • Novel therapies in urothelial carcinoma: A biomarker-driven approach
    Journal Article

    Iyer, G.; Rosenberg, J. E.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1
    Meeting Abstract

    Garon, E.; Wong, D.; Schneider, J.; Aliumaily, R.; Korn, W.; Infante, J.; Patel, M.; Autio, K.; Papadopoulos, K.; Naing, A.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Halabi, S.; Dutta, S.; Tangen, C. M.; Rosenthal, M.; Petrylak, D. P.; Thompson, I. M.; Chi, K. N.; De Bono, J. S.; Fandi, A.; Araujo, J. C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pan-cancer microsatellite instability to predict for presence of Lynch syndrome
    Meeting Abstract

    Latham Schwark, A.; Srinivasan, P.; Kemel, Y.; Shia, J.; Bandlamudi, C.; Mandelker, D.; Dubard-Gault, M.; Tran, C.; Middha, S.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer
    Meeting Abstract

    Vaishampayan, U. N.; Narayan, V.; Wise, D.; Lang, J. M.; Lowentritt, B. H.; Mellado, B.; Carles, J.; Saez, M. I.; Abida, W.; Taplin, M. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist)
    Meeting Abstract

    Slovin, S. F.; Melloni, C.; Mansor-Lefebvre, S.; Neijber, A.; Roe, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC)
    Meeting Abstract

    Tannir, N. M.; Fan, A. C.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Meric-Bernstam, F.; DeMichele, A.; Voss, M. H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC)
    Meeting Abstract

    Teo, M. Y.; Al-Ahmadie, H.; Seier, K.; Ostrovnaya, I.; Regazzi, A. M.; Dalbagni, G.; Bochner, B. H.; Funt, S.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save